share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  08/15 09:27

Moomoo AI 已提取核心訊息

On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer...Show More
On August 15, 2024, Mangoceuticals, Inc., also known as MangoRx, reported substantial growth in its financial results for the first half of 2024. The company, which specializes in men's health and wellness products, including treatments for erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, disclosed a 1,685% increase in shareholders' equity and a 56% increase in year-over-year revenue. Shareholders' equity surged to $13.8 million, up from $774,754 at the end of the previous year, largely due to the acquisition of a patent portfolio from Intramont Technologies. Revenue for the six months ended June 30, 2024, reached $377,258, with a gross profit of $217,190, marking significant growth from the same period in the previous year. CEO Jacob Cohen highlighted the company's focus on innovation and customer satisfaction, with expectations for continued growth in the latter half of the year. MangoRx is also preparing to launch new products, including compounded oral dissolvable tablet (ODT) GLP-1 inhibitors for weight loss and a hormone therapy product for low testosterone. The company's telemedicine platform facilitates the prescription and delivery of its products directly to consumers.
2024年8月15日,MangoRx公司公佈了2024年上半年的財務業績,實現了可觀的增長。該公司專注於男性健康和保健產品,包括治療勃起功能障礙、促進頭髮生長、減肥和激素替代療法等。其中包括股東權益出現了1685%的增長,總收入同比增長了56%。由於收購了Intramont Technologies的專利組合,股東權益激增至1380萬美元,高於去年年底的77.47萬美元。截至2024年6月30日的六個月內,收入達到了377258美元,毛利潤達到了217190美元,這標誌着與前一年同期相比實現了顯著增長。CEO Cohen強調公司專注於創新和客戶滿意度,並期待後半年持續增長。MangoRx還準備推出新產品,包括複方口腔溶解片(GLP-1)以達到減肥效果,和一種低睾酮患者的激素替代治療產品。該公司的遠程醫療平台可以直接向消費者開具處方並提供其產品的配送服務。
2024年8月15日,MangoRx公司公佈了2024年上半年的財務業績,實現了可觀的增長。該公司專注於男性健康和保健產品,包括治療勃起功能障礙、促進頭髮生長、減肥和激素替代療法等。其中包括股東權益出現了1685%的增長,總收入同比增長了56%。由於收購了Intramont Technologies的專利組合,股東權益激增至1380萬美元,高於去年年底的77.47萬美元。截至2024年6月30日的六個月內,收入達到了377258美元,毛利潤達到了217190美元,這標誌着與前一年同期相比實現了顯著增長。CEO Cohen強調公司專注於創新和客戶滿意度,並期待後半年持續增長。MangoRx還準備推出新產品,包括複方口腔溶解片(GLP-1)以達到減肥效果,和一種低睾酮患者的激素替代治療產品。該公司的遠程醫療平台可以直接向消費者開具處方並提供其產品的配送服務。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息